Johnson & Johnson (JNJ)

A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.

The reasons why RBC Capital Markets maintains its stock rating.

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

Investors didn't seem to think so after the company published it.

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.

Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.

Morgan Stanley, Pentair, Johnson & Johnson expected to release earnings, ASML posts strong results, Progressive to report

Johnson & Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead.

Earnings report for JNJ expected on July 15, with analysts predicting $2.85/share & $25.06B revenue. Stock price target raised to $287/share.

The dividend looks secure. The share price is the harder call.

Why are chip stocks collapsing while the Dow barely budges? Korean markets just had their worst day since the 2008 financial crisis, and the fallout is hitting semiconductors hard.

As investors flee this year's high flyers, a few dependable payers are catching the money.

Griffin is at the helm of the world's most profitable hedge fund.

VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.

There are good reasons to invest in Lilly and to hold off.

It's something very simple.